Result of AGM

About this update from Arecor Therapeutics Plc

Arecor Therapeutics plc   ("Arecor", the "Company" or the "Group")   RESULT OF AGM   Cambridge, UK, 2 June 2024: Arecor Therapeutics plc (AIM: AREC) , the biopharmaceutical company advancing today's therapies to enable healthier lives, announces that at its Annual General Meeting, held today at 09.30 am, all eleven resolutions put to members were passed. Resolution 8 was made redundant and bypassed.   The full text of each resolution was included in the Company's Notice of Annual General Meeting made available on the Company's website .   The number of proxy votes cast for and against each of the resolutions proposed, and the number of proxy votes withheld were as follows:   Resolution Votes for % Votes against % Votes withheld Resolution 1 To receive the directors' report, the consolidated financial statements and the auditors' report for the year ended 31 December 2024 17,521,432 100 0 0 174,884 Resolution 2 To approve the directors' remuneration report as set out on pages 36 to 38 in the annual report for the year ended 31 December 2024 15,574,064 91.31 1,481,955 8.69 640,297 Resolution 3 To re-elect Sarah Howell as a Director of the Company in accordance with the articles 17,547,867 100 0 0 148,449 Resolution 4 To re-elect Andrew Richards as a Director of the company in accordance with the articles 16,586,103 94.52 961,764 5.48 148,449 Resolution 5 To re-elect Sam Fazeli as a Director of the Company in accordance with the articles 15,881,200 90.50 1,666,667 9.50 148,449 Resolution 6 To re-elect Jeremy Morgan as a Director of the Company in accordance with the articles 17,547,867 100 0 0 148,449 Resolution 7 To re-elect Christine Soden as a Director of the Company in accordance with the articles 17,547,867 100 0 0 148,449 Resolution 8 To re-elect Alan Smith as a Director of the Company is redundant and was bypassed. Resolution 9 To re-appoint Grant Thornton as auditors of the Company 17,525,016 99.88 21,620 0.12 149,680 Resolution 10 To authorise the Directors to agree the auditors' remuneration 17,537,747 99.94 10,120 0.06 148,449 Resolution 11 To authorise the allotment of shares 16,580,991 99.60 67,376 0.40 1,047,949 Resolution 12 (special) To disapply statutory pre-emption rights 16,580,842 99.93 11,500 0.07 1,103,974   -ENDS-   For more information, please contact:   Arecor Therapeutics plc www.arecor.com Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060 Email: [email protected] David Ellam, Chief Financial Officer Tel: +44 (0) 1223 426060 Email: [email protected]   Singer Capital Markets Advisory LLP (NOMAD and Broker) Phil Davies, Sam Butcher Tel: +44 (0) 20 7496 3000   ICR Healthcare Chris Gardner, David Daley, Lindsey Neville Tel: +44 (0) 20 3709 5700 Email: [email protected]     Notes to Editors   About Arecor Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.  For further details please see our website, www.arecor.com    

View stock analysis, news, and events for Arecor Therapeutics Plc